Merck files Gardasil data for older women with FDA
15 January 2010
Malini Guha
Merck has submitted long-term 48-month data from its Phase III FUTURE trial to the US
FDA with hopes that it will convince the agency to approve its blockbuster cervical cancer vaccine Gardasil in older women, aged 27-45. The FDA has accepted the filing and the company is anticipating a decision within...
Please Login to read the full article.
15 January 2010
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Canada extends Gardasil label to include women aged up to 45
- HHS chief invokes authority to force rejection of broad Plan B OTC sales
- Gilead's Truvada cut risk of HIV infection by up to 78% in heterosexuals
- Photocure set for 2012 completion of Phase II Cevira trial for cervical HPV
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
